Advice
following a full submission:
cladribine (Mavenclad®) is accepted for restricted use within NHSScotland.
Indication under review: for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features.
SMC restriction: for use in patients with active relapsing-remitting multiple sclerosis (RRMS)
In a phase III study, cladribine showed statistically significant improvements in the annualised relapse rate in adults with active relapsing-remitting MS, compared with placebo.
Medicine details
- Medicine name:
- cladribine (Mavenclad)
- SMC ID:
- SMC2751
- Indication:
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features.
- Pharmaceutical company
- Merck Serono Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 June 2025